Genovis AB (publ.) (GENO.ST) Stock Analysis & AI Equity Report
Genovis AB (publ.) (GENO.ST) overview
Genovis AB (publ.) (GENO.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, Genovis AB (publ.) reported revenue of SEK 130m and operating profit of SEK 45.7m; the year-end share price was 24.70 SEK and market capitalisation was SEK 1,617m. Genovis AB (publ.) is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Genovis AB (publ.)'s valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-18. Data will be refreshed during report generation.
About Genovis AB (publ.)
Genovis AB develops and sells enzyme-based tools and related services for the biopharmaceutical and research industries. Its SmartEnzymes portfolio and antibody-focused offerings support protein characterization, glycan analysis, bioconjugation, and quality control in drug development, manufacturing, and diagnostics. The company serves scientists and pharmaceutical customers through product sales and specialized services.
Generate the Genovis AB (publ.) report
Genovis AB (publ.) is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Genovis AB (publ.) and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.